Holly Schmidt
About Holly Schmidt
Holly Schmidt is a Principal Scientist at Bristol Myers Squibb with extensive experience in biochemistry and drug development.
Current Role at Bristol Myers Squibb
Holly Schmidt currently serves as a Principal Scientist at Bristol Myers Squibb. In this role, she leads matrix teams focused on optimizing the expression, purification, and analysis of reagents and diagnostic tools. She also plays a key role in the early development of drug candidates. Her work is centered around creating and characterizing multispecific binders, monoclonal antibodies (mAbs), Adnectins, and antibody-drug conjugates (ADCs) to treat cancer resistance, fibrosis, and immune disorders.
Previous Role at Adnexus
From 2009 to 2018, Holly Schmidt worked for nine years as a Senior Research Scientist at Adnexus in Waltham, Massachusetts. During her tenure, she gained extensive experience in advanced research, contributing to the development of innovative therapies and improving existing methodologies. Her work primarily focused on biochemistry and molecular biology techniques, reinforcing her expertise in the field.
Background at Pfizer
Holly Schmidt began her career at Pfizer as a Staff Scientist, where she worked from 1993 to 2001 in Cambridge, Massachusetts. Over the course of eight years, she developed a strong foundation in biochemical research and pharmaceutical development. This early experience paved the way for her subsequent roles in the industry, emphasizing her long-standing commitment to advancing biotechnological sciences.
Educational Background in Biology
Holly Schmidt studied Biology at the College of the Holy Cross, earning her Bachelor's degree from 1987 to 1991. This academic foundation provided her with essential knowledge and skills in the biological sciences, enabling her to pursue a successful career in research and biochemistry.
Notable Collaborations and Projects
Holly Schmidt has been involved in significant collaborations throughout her career. In 2019, she actively collaborated with Johns Hopkins on a High Throughput MAPPS evaluation project to determine MHC class II epitopes in candidate molecules. From 2019 to 2022, she worked with MIT Pentilute Lab, bridging biochemistry techniques to Chemistry Postdoctoral researchers. These collaborations highlight her commitment to advancing scientific research through partnership and innovation.